Caminsky N., Mucaki E.J., Rogan P.K. Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis // F1000Res. 2014. 3. 282.
Cheung K-J.J., Horsman D.E., Gascoyne R.D. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target // Br. J. Haematol. 2009. 146. 257–269.
Diederichs S., Bartsch L., Berkmann J.C., Fröse K., Heitmann J., Hoppe C. The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations // EMBO Mol. Med. 2016. 8. (5). 442-57.
Enomoto Y., Kitaura J., Hatakeyama K., Watanuki J., Akasaka T., Kato N. Emu/miR-125b transgenic mice develop lethal B-cell malignancies // Leukemia. 2011. 25. (12). 1849-1856.
Flowers C R., Sinha R., Vose J.M. Improving outcomes for patients with diffuse large B-cell lymphoma // Cancer J. Clin. 2010. 60. 393–408.
Krug U., Ganser А., Koeffler Н.Р. Tumour suppressor genes in normal and malignant hematopoiesis // Oncogene. 2002. 21. 3475–3495.
Leroy B., Fournier J.L., Ishioka C., Monti P., Inga A., Fronza G. The TP53 website: an integrative resource centre for the TP53mutation database and TP53mutant analysis // Nucl. Acids Res. 2013. 41. D962– D969.
Liu Y.Y. PTEN tumor suppressor plays less prognostic role than p53 tumor suppressor in diffuse large B-cell lymphoma // Leuk. Lymph. 2010. 51. (9). 1692–1698.
Miyazaki K. Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity // Rinsho Ketsueki. 2015. 56. (10). 2047-2055.
Olivier M., Hollstein М., Hainaut Р. TP53mutations in human cancers: origins, consequences, and clinical use // Spring Harb. Perspect. Biol. 2010. 2. a001008.
Poddubyaja I.V. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Moscow: Media Medika, 2013. 104 p. [In Russian].
Soussi T., Kato S., Levy P.P., Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutation // Hum. Mutat. 2005. 25. 6-17.
Stefancikova L. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma // Int. J. Oncol. 2011. 39. 1413-1420.
Sturm I. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy // Cell Death Differ. 2003. 10. (4). 477-484.
Tamimi Y. The p53 mutation/deletion profile in a small cohort of the Omani population with diffuse large B-cell lymphoma // Sultan Qaboos Univ. Med. J. 2014. 14. (1). 50-58.
van de Schans S.A. Improving relative survival, but large remaining differences in survival for non-Hodgkin’s lymphoma across Europe and the United States from 1990 to 2004 // J. Clin. Oncol. 2011. 29. (2). 192–199.
Voropaeva E.N., Pospelova T.I., Voevoda M.I., Maksimov V.N. Comparative analysis of TP53 gene mutations in patients with DLBCL of Novosibirsk with data presented in IARC TP53 mutation database. Medicinskaya genetika = Medical Genetics. 2016. 15. (4). 17-20. [In Russian].
Voropaeva E.N., Pospelova T.I., Voevoda M.I., Maksimov V.N. Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma // Mol. Biol. (Mosc.). 2017. 51. (1). 53–60.
Xu-Monette Z.Y. Mutational profile and prognostic significance of TP53in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCLRituximab-CHOP Consortium Program Study // Blood. 2012. 120. 3986–3996.
Xu-Monette Z.Y., Medeiros L.J, Li Y., Orlowski R.Z., Andreeff M., Bueso-Ramos C.E. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies // Blood. 2012. 119. (16). 3668–3683.
Young K.H., Leroy K., Møller M.B., Colleoni G.W., Sánchez-Beato M., Kerbauy F.R., Haioun C. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study // Blood. 2008. 112. (8). 3088--98.
Zhang M., Heldin A., Palomar-Siles M., Öhlin S., Bykov V.J.N., Wiman K.G. Synergistic rescue of nonsense mutant tumor suppressor p53 by combination treatment with aminoglycosides and Mdm2 inhibitors // Front. Oncol. 2018. 7. 323.